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SUMMARY KEY WORDS
AtT-20 cells, which produce [-endorphin,
and AtT-20/hENK cells, which are AtT-20 cells
transfected with a proenkephalin gene, were
implanted in the rat spinal subarachnoid space
in an effort to produce an antinociceptive effect.
Host rats were tested for antinociceptive activity
by standard nociceptive tests, tail flick and hot
plate. Although cell implants had minimal effect
on the basal response to thermal nociceptive
stimuli, administration of the 12-adrenergic
agonist isoproterenol produced antinociception
in the cell-implanted group but not in the
control group. The antinociceptive effect of
isoproterenol was dose-related and could be
blocked by the opioid antagonist naloxone.
Immunohistochemical analysis of spinal cords
revealed the presence of enkephalin-negative
cells surrounding the spinal cord of rats
receiving AtT-20 cell implants, and enkephalin-
positive cells surrounding the spinal cord of rats
receiving AtT-20/hENK cell implants. These
results suggest that opioid-releasing cells
implanted around rat spinal cord can produce
antinociception and may provide an alternative
therapy for chronic pain.
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INTRODUCTION
Analgesics remain under-administered in
chronic and terminal cancer patients/5/. Although
recently developed procedures for continuous
infusion of opioids at the spinal level provide
powerful analgesic effects, the infusion may fail
when problems occur related to the infusion
catheter, such as infection, occlusion or catheter
dislocation /10,13,23,25/. Therefore, alternative
ways to control pain are desirable. One approach
may be to implant tissues or cells that secrete
analgesic substances around the spinal cord to
reduce the spinal transmission of pain. Spinal
implantation of adrenal medullary chromaffin cells,
cells known to release opioids and catecholamines,
resulted in measurable antinociception in rats
/32,33/, in decreased indications of pain in a rat
model/3/of neuropathic pain/12/and in pain relief
in terminal cancer patients /34/. In view of the
difficulty associated with obtaining adrenal cells,
an alternative source of opioid-secreting cells for
transplantation would be useful. In the present
study, two mouse cell lines, AtT-20 and AtT-
20/hENK, were tested for antinociceptive
properties when implanted adjacent to the spinal
cord in the rat.
AtT-20 cells were originally derived from a
mouse anterior pituitary tumor /6/. These cells
synthesize and secrete the opioid peptide I-
endorphin /15,20,29/. I-Endorphin, when
administered intrathecally, produced antinoci-
ception in rats/11,45,46/and analgesia in humans
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/24,40/. The genetically modified AtT-20/hENK
cell line was derived from the AtT-20 line by
introduction of a plasmid containing the human
proenkephalin gene /8/. These cells express
proenkephalin protein which is cleaved to form free
enkephalins. Enkephalins, when administered
intrathecally, have also been shown to produce
antinociception in rat /45,47/ and mouse /17/. It
was expected that the 13-endorphin released from
AtT-20 cells or the 13-endorphin and enkephalin
released from AtT-20/hENK cells following
implantation adjacent to the spinal cord would
result in reduced pain sensitivity in host animals.
Release of opioids from these cells can be
enhanced by certain drugs in culture. 3-Endorphin
release from AtT-20 cells was increased by
corticotropin releasing factor (CRF) stimulation
/1,2/. This action was suggested to involve
increased production of cAMP /2/. Therefore,
intrathecally administered CRF should provide a
way to enhance antinociceptive effects of the
implanted cells by increasing 13-endorphin release.
However, the utility of CRF for these studies is
confounded by the recent finding that CRF has
spinal antinociceptive activity of its own through :
opioid receptors in the writhing test /38/ and
antagonizes morphine antinociception in the tail
flick test/37/; therefore, an alternative method was
sought to promote opioid secretion from these
cells. AtT-20 cells possess 13-adrenoceptors
coupled to a stimulatory G-protein, which, when
activated, increases cAMP production/28/. The -
adrenergic agonist isoproterenol stimulated ACTH
release from AtT-20 cells/2,28/. Since CRF and
isoproterenol stimulate cAMP formation and
ACTH release through parallel mechanisms
/19,27/, it was predicted that isoproterenol, like
CRF, would also stimulate 13-endorphin release
from AtT-20 cell implants. Unlike CRF,
isoproterenol has been reported to have no
antinociceptive activity by itself /22,48/; an
antinociceptive effect induced by isoproterenol
would most likely result from stimulation of opioid
secretion from the implanted cells. Therefore,
isoproterenol administered intrathecally was used
as a stimulator of opioid secretion in the present
study.
The results of this study showed that
intrathecally implanted AtT-20 cells had an
antinociceptive effect when stimulated by iso-
proterenol. Isoproterenol-induced antinoeieeption
in rats implanted with AtT-20 cells was blocked by
the opioid antagonist naloxone, suggesting that 13-
endorphin secretion from the implants accounted
for this activity. Isoproterenol also produced
antinociception in rats implanted with AtT-
20/hENK cells. Preliminary results have been
reported previously in abstract form/44/.
MATERIALSAND METHODS
Cell culture and preparation for Implantation
AtT-20 cells and AtT-20/hENK cells (a gift
from Dr. M. Martin) were grown in Ham’s F-10
medium containing 12% horse serum and 3% fetal
calf serum under 10% CO2 and 90% air at 37"C.
The cells were removed from the culture flasks,
centrifuged at 500 g for 5 minutes, resuspended in
PBS (10 mM phosphate / 0.9% NaCI, pH 7.4)
solution and counted using a hemocytometer. The
cells were again centrifuged and resuspended in
PBS at various concentrations for intratheeal (i.t.)
administration to recipient animals.
Animals and cell implantation
Recipients were male Sprague-Dawley rats
weighing 75-100 g (Harlan Sprague-Dawley,
Madison, WI). Small rats (one month old) were
used to facilitate i.t. injection by direct lumbar
puncture. Animals were maintained on a 12-hour
light/dark cycle with chow and water available ad
libimm. Ten tl cell suspensions containing 106
cells were injected into the lumbar subarachnoid
space according to the direct lumbar puncture
technique described by Hylden and Wilcox /16/
and as modified by Wilcox/41/. The number of
cells used per animal was determined by the
maximum number of cells that could be easily
suspended in 10 tl of medium and injected though
a 27 ga needle. The effect of different volumes of
cell suspension was not examined in the present
study. In the experiments using isoproterenol
stimulation, 10 tl of cell suspensions containing 4
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x 105 cells were used. All i.t. injections in the
present experiments were via 1 cm 27 ga needles.
Control animals received 10 lxl PBS i.t. During the
three week duration of an experiment, the motor
ability of animals was observed daily, and the
animals were weighed every other day during the
first week and weekly thereafter.
Antinociceptive testing
Nociceptive sensitivity was measured before
and 1, 3 and 5 days after cell implantation. Two
standard nociceptive tests, tail flick and hot plate,
were used sequentially. For the tail flick test, a
radiant heat source was applied to the tail/9/, and
the time required for the animal to remove its tail
from the heat source was measured. The baseline
response time in the absence of treatment was 3.0 +/-
0.1 seconds, and the cut-off time was set at 10
seconds. In the hot plate test the temperature of an
aluminum plate (20 x 35 cm) in a clear plastic
enclosure (34 cm high) was maintained at 52"C
(+/- 0.5"C) by circulating hot water /42/. Each
subject was placed on the hot plate and the latency
to jump or lick its hind paw was measured. The
baseline response time in the hot plate test was 24
+/- 2 seconds and the cut-off time was set at 60
seconds. These maximum cut-off latencies were set
to avoid tissue damage and were determined to be
more than three standard deviations above the
control mean for several pooled groups of control
animals. The percent maximum possible effect
(MPE) was determined in the usual way [% MPE
(postdrug latency predrug latency)/(cut-off-
predrug latency) x 100%].
Drugs and procedures for antinociceptive testing
Isoproterenol (Aldrich Chemical Company,
Inc., Milwaukee,WI) was prepared in physiological
saline containing the cAMP phosphodiesterase
inhibitor ZK 62711 (a gift from Dr. P. Y. Law).
The ZK 62711 was dissolved in absolute ethanol
(30 mg/ml) then diluted with physiological saline
to a final ethanol concentration of 1.0%. Naloxone
hydrochloride (E.I. Dupont Co., Garden City, NJ)
was prepared in physiological saline (0.3 mg/ml).
Two to 9 days after cell implantation, the drugs
were given by i.t. injection. All i.t. injections were
made in a volume of 10 Ixl. Nociceptive sensitivity
was measured before and after drug application.
The drug experiments using i.t. injection were
limited to 9 days after cell implantation because the
increased size of the rats after this point made
intrathecal drug injections more difficult. We were
therefore unable to follow the antinocieeptive
effects of the implants at later times.
Immunohistochemistry
Three days after cell implantation, 2 rats of each
cell-implanted group were anesthetized with ether
and perfused with 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). The spinal cords were
removed and post fixed in 4% paraformaldehyde
for 2 hours at 4"C, then placed in 20% sucrose / 0.1
M phosphate buffer overnight at 4"C. The spinal
cords were embedded in tragacanth gum and
sectioned on a cryostat at 12 tm. Sections were
incubated in rabbit anti-met-enkephalin antisera (a
gift from Dr. R. P. Elde) at 1:100 in PBS /21/
followed after rinsing by incubation in goat-anti-
rabbit IgG antibody conjugated to fluorescein
isothiocyanate (Jackson Immunoresearch Laborato-
ries, Inc.) at 1:500 in PBS. The sections were
examined and photographed with a microscope
under epifluorescence illumination.
Statistical analysis
Statistical analyses were performed using
analysis of variance (ANOVA) followed by the
Fisher PLSD test for multiple post-hoe
comparisons among groups. Differences were
considered to be significant if p<0.05.
RESULTS
Nociceptive thermal responses after AtT-20 and
AtT-20/hENK cell implants
Three groups of 22 rats each received an i.t.
injection of AtT-20 cells, AtT-20/hENK cells or
PBS. The rats were tested in the tail flick and hot
plate tests 1 day before and 1, 3 and 5 days after
implantation. Pre- and post-cell implantation, the
tail flick and hot plate response latencies to
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nociceptive stimuli were compared. In the tail flick
test, the degree of antinociception (% MPE) of the
group receiving AtT-20/hENK cell-implants was
higher than that of the AtT-20 cell-implanted group
and the control group (Fig. 1A). There was no
evidence for antinociception with any of the three
groups in the hot plate test (Fig. 1B).
Effects of isoproterenol
Because basal opioid release from the implanted
cells appeared inadequate to produce substantial
antinociception, we sought to increase the opioid
secretion from the cell implants by stimulation with
the 13-adrenergic agonist isoproterenol. Three days
after implantation of AtT-20 cells, isoproterenol
was coadministered with 10 ktg ZK 62711, a
phosphodiesterase inhibitor /35/. ZK 62711 was
used to reduce enzymatic destruction of cAMP and
to prolong the effect of isoproterenol/4,36/. This
dose of ZK 62711 alone affected neither the tail
flick nor the hot plate latencies post drug injection
(Fig. 2). In the tail flick test the antinociceptive
effect of isoproterenol (40 nmol, i.t.) in rats
receiving AtT-20 implants was significantly higher
than control groups at 3 and 10 minutes (Fig. 2). At
3 minutes in the hot plate test, both the AtT-20 and
control groups showed an antinociceptive effect;
the effect in the control group was considered to be
due to the stress of handling during the injection.
At 10 minutes in the hot plate test, partial
antinociception was maintained in the AtT-20 cell-
implanted group but not in the control group.
Nine days after AtT-20 cell implantation, tail
flick and hot plate response latencies were
determined before and 5 minutes after
isoproterenol injection. Before isoproterenol, tail
flick and hot plate response latencies showed no
difference between AtT-20 cell-implanted and
control groups. However, isoproterenol (12, 40 and
120 nmol i.t. coadministered with ZK 62711)
troduced dose-related tail flick (Fig. 3A) and hot
plate (Fig. 3B) antinociception in the AtT-20 cell-
implanted group. The highest dose of isoproterenol
(120 nmol) did not produce antinociception in the
control group. The anticiceptive effect of
isoproterenol in the AtT-20 cell-implanted group
could be blocked by coadministration of the opioid
antagonist naloxone (3tg, i.t.), a dose that had no
effect on its own in any of the three groups.
Isoproterenol also produced antinoeieeption in
rats receiving AtT-20/hENK cell implants,
although these cells had lower apparent efficacy
than AtT-20 cells. Figure 4 presents the results for
eight individual rats 2 days after receiving AtT-
20/hENK cells. Four rats showed higher tail flick
response latency at 5 minutes after receiving
isoproterenol (12 nmol, i.t.) than that of the control
group. The antinociceptive effect of 12 nmol
isoproterenol was smaller with AtT-20/hENK cell
implants (19+/-5% MPE) than that observed with
AtT-20 cell implanted rats (41+/-14% MPE).
Rat hosts
Intrathecal implantation of AtT-20 cells was not
lethal to host rats. The size and the motor ability of
7 rats receiving 106 AtT-20 cells did not differ from
control rats for as long as six months following cell
implantation (data not shown). The growth rate of
the rats, however, was decreased in the AtT-
20/hENK cell-implanted group (Fig. 5). Also,
seven days after AtT-20/hENK cell implantation,
43% of host rats manifested hind limb paralysis,
indicating that AtT-20/hENK cells may differ from
AtT-20 cells in their metastatic potential.
Immunohistochemistry
Three days after cell implantation, the spinal
cords of rats from the three groups were examined
histologically. Sections of spinal cords processed
for enkephalin immunoreactivity revealed the
presence of enkephalin-positive cells around the
spinal cord of an AtT-20/hENK cell-implanted rat
(Fig. 6A,C), and the presence of enkephalin-
negative cells around the spinal cord of an AtT-20
cell-implanted rat (Fig. 6B,D). No cells were seen
around the spinal cord of control rats.
DISCUSSION
The present study showed that intrathecal
implantation of AtT-20 or genetically modified
AtT-20/hENK cells had an antinociceptive effect
apparently mediated by opioid receptors. This
effect was revealed when the cell implants were
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The percent maximum possible effect (%MPE) of base line tail flick (A) and hot plate (B) latencies in rats after receiving
106 AtT-20 cells, 106 AtT-20/hENK cells or no cells i.t. In the tail flick test, a two-factor, repeated measures ANOVA
showed significant differences among the three groups (F2,63=5, p<0.01). The AtT-20/hENK cell-implanted group
showed more antinociception than the AtT-20 cell-implanted and control groups. Significant post-hoe comparisons are
indicated by *(p<0.05). In the hot plate test, a two-factor, repeated measures ANOVA showed no significant differences
among the three groups (F2,63=1.8, p=0.12). Each point represents the mean +/- SEM (22 rats in each group).
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Fig. 2: The [3-adrenergic agonist isoproterenol (40 nmol, i.t.) together with the cAMP phosphodiesterase inhibitor ZK 62711 (10
tg, i.t.) in rats 3 days after receiving 4 x 105 ART-20 cells i.t. produces antinociception in the tail flick test. A three-factor
repeated measures ANOVA indicated that the antinociceptive effect of isoproterenol was statistically significant
(F1,24=16, p<0.001). Significant post-hoc comparisons are indicated by (p<0.05). The AtT-20 cell-implanted group















Fig. 3: Dose-related, isoproterenol-induced antinociception (12, 40 or 120 nmol isoproterenol) together with the cAMP
phosphodiesterase inhibitor ZK 62711 (10 tg, i.t.) in rats 9 days after receiving 4 x 105 ART-20 cells i.t. was blocked by
the opioid antagonist naloxone (3 .ug, i.t.)in the tail flick (A) and hot plate (B) tests. Each point represents the mean +/-
SEM (5 rats in each group).
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The 13-adrenergic agonist isoproterenol (12 nmol, i.t.) together with the cAMP phosphodiesterase inhibitor ZK 62’711 (10
pg, i.t.) produced antinociception in the tail flick test in rats 2 days after receiving 106 AtT-20/hENK or 3 days after
receiving 4 x 105 AtT-20 cells i.t. A one-factor ANOVA indicated a statistically significant (F2,1=5, p<0.05)
antinociceptive effect of isoproterenol in the AtT-20/hENK cell-implanted group compared with the control group. There
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The body weight of rats receiving 106 ART-20 cells or 106 AtT-20/hENK cells i.t. The weight gain of rats receiving AtT-
20 cells did not differ from control. The AtT-20/hENK cell-implanted group had lower weight gain than the ART-20 cell-
implanted or control groups during 10 days after cell implantation (two-factor, repeated measures ANOVA, F2,18=9,
p<0.005). Significant post-hoe comparisons are indicated by *(p<0.05). Each point represents the mean SEM (’7 rats in
each group).
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pharmacologically stimulated to secrete opioids by
administration of isoproterenol.
AtT-20/hENK cell implants produced a partial
antinociceptive effect in the tail flick test. AtT-20
cell implants did not affect the baseline tail flick
response latency, and neither AtT-20 nor AtT-
20/hENK cell implants affected the baseline hot
plate response latency. This result agrees with
observations made with adrenal medullary
chromaffin cell implants /32/. This lack of
antinociception in the tail flick and hot plate tests
does not completely discount the analgesic utility
of such cell implants. Despite failure of adrenal
medullary chromaffin cell implants in rat spinal
cord to alter the baseline tail flick and hot plate
latencies, implants in rats with neuropathic pain
/12/ and humans with terminal cancer pain /34/
were effective.
The effect of implant-induced antinociception in
the absence of cell stimulation was minimal with
AtT-20 cell implants and small but significant with
AtT-20/hENK cell implants in the tail flick test.
This may be due to a low spontaneous secretion of
opioid by these cells/8,15/. It was reasoned that
antinociception might be revealed by use of a
pharmacological agent to stimulate opioid secretion
from the implants. A similar observation was
reported with adrenal medullary chromaffin cell
implants, which produce antinociception only after
nicotine stimulation of release of opioid peptides
and catecholamines from the implants/30-32/. Our
results showed that isoproterenol produced
antinociception in rats implanted with AtT-20 or
AtT-20/hENK cells. Since isoproterenol is able to
s.timulate release from AtT-20 cells in vitro/2,28/,
the antinociceptive effects of isoproterenol in rats
receiving AtT-20 cell implants probably resulted
from [3-endorphin secretion from the implants. The
observation that isoproterenol-induced anti-
nociception in the AtT-20 cell-implanted rats was
completely blocked in the tail flick test and
partially blocked in the hot plate test by the opioid
antagonist naloxone supports this contention.
Our results indicate that antinociception
produced by isoproterenol lasts only about 10
minutes. Stress-induced analgesia cannot account
for all the antinociception observed because control
groups, which received the same injections,
showed little antinociception and because the
effects of these cell stimulators were dose-related.
The short duration of antinociception may result
from other causes. It has been shown that the
duration of antinociception induced by spinal
administration of [3-endorphin is dose-dependent: 1
nmol 13-endorphin i.t. lasts for 1 hour and 10 nmol
13-endorphin i.t. lasts for 2 hours, while 0.1 nmo113-
endorphin i.t. is inactive /11/. The amount of 13-
endorphin secreted from the implants may be quite
small, yielding only a short duration of action. In
addition, we have observed that mice receiving
AtT-20 cell implants developed tolerance to
opioids (i.t.)/43/. Rats implanted with AtT-20 cells
may also develop tolerance to [3-endorphin,
reducing the response to 13-endorphin released from
the cell implants by isoproterenol stimulation.
Furthermore, [3-adrenergic receptor desensitization
/14,36/ may contribute to the short duration of
isoproterenol antinociception.
Contrary to Yaksh’s observation /22,48/, the
present results indicate that isoproterenol induced a
small antinociceptive effect in control rats.
Differences in the i.t. injection method between our
laboratory and Yaksh’s laboratory may account for
this difference. Yaksh’s group used chronic
indwelling intrathecal catheters, while the present
study used direct lumbar puncture to deliver
isoproterenol. The small antinociceptive effect
observed in the present study may result from the
stress of handling during the drug injection.
AtT-20/hENK cell implants secrete enkephalin
in addition to [5-endorphin. Since both enkephalin
and 13-endorphin produced antinociception when
administered to the spinal cord /45-47/, it was
expected that AtT-20/hENK cell implants might
result in a greater antinociceptive effect than that
detected with AtT-20 cell implants. The present
study showed that unstimulated AtT-20/hENK cells
produced more antinociception in the tail flick test
than that produced by AtT-20 cell implants. By
contrast, isoproterenol stimulation produced more
antinociception with AtT-20 cells than with AtT-
20/hENK cells. It has been reported that met-
enkephalin antagonizes while leu-enkephalin
potentiates morphine antinociception /7,18,26,39/.
The proenkephalin gene transfected in genetically
modified AtT-20/hENK cells contains six met-
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enkephalin sequences and one leu-enkephalin
sequence/8/. The preponderance of met-enkephalin
in AtT-20/hENK cells might modulate 13-endorphin
antinociception negatively, reducing antinocicept-
ion in AtT-20/hENK cell-implanted rats.
The present study showed that rat hosts
survived indefinitely with intrathecal implantation
of AtT-20 cells but not with AtT-20/hENK cells.
Preliminary studies showed that when AtT-20 and
AtT-20/hENK cell-implanted rats were treated
daily with the immunosuppressant cyclosporin A (1
mg/kg, i.p.) after implantation, both groups of rats
lost weight and developed hind limb paralysis
within 7 days. It was observed that the growth of
AtT-20 and AtT-20/hENK cell lines in culture
exhibited different characteristics. The AtT-20 cells
floated in culture media while most of the AtT-
20/hENK cells adhered to the bottom of the culture
flasks. The different characteristics exhibited by
AtT-20 and AtT-20/hENK cells in culture may
reflect differences in the metastatic potential of the
two cell lines. Interestingly, mice injected with
fewer cells (105) remained healthy for at least 1
month/43/.
Histological studies suggested that both AtT-20
and AtT-20/hENK cells survived implantation.
Immunohistochemistry showed the presence of
enkephalin-positive cells surrounding the spinal
cords of AtT-20/hENK cell-implanted rats. Cells,
which were not present in control animals,
surrounded the spinal cords of AtT-20 cell-
implanted rats, but these were enkephalin-negative.
This result was as expected, because only the
genetically modified AtT-20/hENK cell line
secretes enkephalin/8/.
This study has identified and characterized
pharmacologically an antinociceptive effect of
opioid-producing AtT-20 and genetically modified
AtT-20/hENK cells implanted around rat spinal
cord. Implantation of cell lines may provide a
method to control chronic pain in patients. The
present study is an initial step in the development
of cell lines for transplantation in pain syndromes.
In future studies, it will be important to determine
whether the implanted cells release opioid peptides
for long periods post implantation, and whether
encapsulation of the implanted cells would reduce
the metastatic potential of the cells without
compromising their antinocieeptive effect.
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